TRAINING IN THE IMMUNOBIOLOGY AND MOLECULAR CELL BIOLOGY OF CANCER

项目摘要 这一修订后的申请寻求T32计划的36-40年延期， 为7名博士后MD，PhD或MD/PhD科学家提供培训。培训 该计划集中在病理学和免疫学系（P&I）， 圣路易斯的华盛顿大学，由36名培训导师组成， 分布在10个不同的部门培训教师由16名妇女组成， 20人，包括2名URM。教师是一个高度互动的群体， 对癌症免疫学和细胞/分子癌症感兴趣的免疫学家 生物学，并由主任和副主任谁是众所周知的， 对癌症免疫学/免疫治疗的贡献，以及他们对 培养青年科学家。我们学院的研究集中在各个方面 癌症免疫学和免疫治疗的重点是分子基础 细胞的激活和抑制。由六名T32教师组成的指导委员会 成员监督培训计划，并负责选择和 对学员的监督。我们还成立了一个新的外部咨询委员会， 外界对我们T32项目的看法培训包括为期2至3年的全面培训， 时间实验室研究，在那里受训者接触到最新的方法， 癌症免疫学和细胞与分子癌症生物学。培训还 包括在实验室会议上发言，参加每周一次的研讨会， 每年务虚会，研究伦理和严谨性和可重复性的培训，参与 参加国家/国际会议和机会， 免疫学、细胞生物学和癌症生物学。在最近的10年里， 在T32资助期内，49名学员得到了该计划的支持：4人退出 由于个人原因，7名刚开始参加该项目的学员在工作中 因新型冠状病毒疫情而推迟。其余38名学员发表了171 论文，其中33篇论文发表在高影响力期刊上，76%的学员 至少有一篇第一作者论文在70名曾经或正在接受培训的学员中， 在过去15年中，在该方案的支持下，66个国家（94%）继续从事研究工作。 这些人口统计数据证明了我们的T32培训计划的成功， 为其竞争力的提升提供有力支撑。

PROJECT ABSTRACT This revised application seeks renewal for years 36-40 of a T32 program that will provide training for 7 postdoctoral MD, PhD or MD/PhD scientists. The training program is centered in the Department of Pathology and Immunology (P&I) at Washington University in St. Louis, and consists of 36 training mentors who are housed in 10 different departments. The training faculty consists of 16 women and 20 men and includes 2 URM. The faculty are a highly interactive group of immunologists with interests in cancer immunology and cell/molecular cancer biology and are led by a director and associate director who are well known for their contributions to cancer immunology/immunotherapy and their commitment to training of young scientists. The research of our faculty focuses on various aspects of cancer immunology and immunotherapy with an emphasis on the molecular basis of cellular activation and suppression. A Steering Committee of six T32 faculty members oversees the training program and is responsible for the selection and oversight of the trainees. We also formed a new external advisory board to obtain outside opinions on our T32 program. Training includes a 2-to 3-year period of full- time laboratory research, where the trainee is exposed to the latest approaches in cancer immunology and cell and molecular cancer biology. The training also includes presenting at laboratory meetings, participation in weekly seminars and yearly retreats, training in research ethics and rigor and reproducibility, participation in national/international meetings and opportunities to audit advanced courses in Immunology, Cell Biology and Cancer Biology. During the most recent 10-year funding period of this T32, 49 trainees were supported by the Program: 4 withdrew for personal reasons and 7 trainees who had just started the program had their work delayed by the COVID-19 pandemic. The remaining 38 trainees published 171 papers with 33 papers appearing in high impact journals and 76% of these trainees had at least one first-author paper. Of the 70 trainees who have been or are supported by this Program in the last 15 years, 66 (94%) have remained in research. These demographics document the success of our T32 Training Program and provide strong support for its competitive renewal.